Skip to main content
. Author manuscript; available in PMC: 2011 Jul 9.
Published in final edited form as: J Urol. 2010 May;183(5):1816–1821. doi: 10.1016/j.juro.2010.01.011

Table 1.

Clinical and pathologic characteristics of the study population.

Race
 White
 Black
 Other
 Unknown
1102 (91%)
48 (4%)
8 (1%)
50 (4%)
Total PSA
 Mean, Median (range)
 <2.5
 2.6–4.0
 4.1–10.0
 >10.0
5.0, 4.4, (0.2–45.3)
139 (11.5%)
335 (27.7%)
675 (55.9%)
59 (4.9%)
Clinical Stage
 T1 a/b
 T1c
 T2
 Missing
12 (1%)
805 (66.6%)
386 (32%)
5 (0.4%)
Biopsy Gleason Score
 Mean, Median (range)
 ≤6
 7
 8–10
 Missing
5.5, 6.0 (2.0 – 10)
961 (79.5%)
106 (8.8%)
40 (3.3%)
101 (8.4%)
PSADT Distribution
 Mean, Median (range)
 ≤0*
 0–12 mos.
 12–24 mos.
 24–36 mos.
 36–48 mos.
 48–60 mos.
 60–99 mos.
 100 mos.
50.5, 34.5 (1 – 100)
267 (22%)
200 (17%)
267 (22%)
154 (13%)
79 (7%)
52 (4%)
64 (5%)
125 (10%)
Organ-Confined 905 (74.9%)
Extracapsular Extension 129 (10.7%)
Positive Surgical Margins 239 (19.8%)
Seminal Vesicle Invasion 31 (2.6%)
Lymph Node Metastases 5 (0.4%)
Prostatectomy Gleason score ≥7 282 (23.3%)
*

Classified as 100 months in the overall analysis, excluded in subgroup analysis.